News and Updates

New research explores how daily probiotics influence the gut-brain axis to alleviate symptoms of depression and anxiety. Learn the science behind it.

Adaptive Deep Brain Stimulation is forcing a rethink of CNS clinical trial design. Can new data models meet FDA requirements for this life-changing tech?

Zabopegdutide shows 81.8% fibrosis response in Phase 2 MASH trials. Discover how this potential breakthrough treatment impacts liver health and prognosis.

uniQure announces BLA submission plans for AMT-130, a breakthrough gene therapy targeting the root cause of Huntington’s disease. Learn the latest updates.

Olorofim hits Phase 3 non-inferiority goals for treating Invasive Aspergillosis, offering a new hope for patients with drug-resistant fungal infections.

The FDA is reviewing a new Lunsumio and Polivy combo for relapsed B-cell lymphoma. Discover how this dual-targeted therapy could transform patient outcomes.

The FDA has approved Utebzi, the first oral carbapenem for complicated UTIs. Learn how this breakthrough antibiotic is transforming outpatient clinical care.

A landmark clinical trial is testing senolytic drugs to clear aging "zombie cells." Discover how this could revitalize the immune system and fight aging.

New clinical findings reveal that daily postbiotic gummies can reduce gum bleeding in just six weeks, offering a promising new tool for oral health care.

Biogen confirms the acquisition of RayThera to expand its immunology pipeline. Discover how this strategic move strengthens its position in autoimmune therapy.